AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AcelRx Pharmaceuticals Inc (ACRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9866
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. Its pipeline also includes Zalviso, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. The company commercializes its EC approved Zalviso under license agreement with Grunenthal in various European Union countries and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
Partnerships 12
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
Equity Offering 14
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
Asset Transactions 22
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc – Key Competitors 24
AcelRx Pharmaceuticals Inc – Key Employees 25
AcelRx Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 02, 2018: Acelrx Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 27
Aug 02, 2018: AcelRx Pharmaceuticals reports second quarter 2018 financial results 28
May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 29
Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 30
Nov 09, 2017: AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 01, 2017: AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 32
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 34
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 36
Corporate Communications 38
Oct 12, 2018: AcelRx Pharmaceuticals Stock Trading Halted 38
Jul 19, 2017: AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer 39
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc, Key Competitors 24
AcelRx Pharmaceuticals Inc, Key Employees 25
AcelRx Pharmaceuticals Inc, Subsidiaries 26

List of Figures
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lion Energy Ltd (LIO):企業の財務・戦略的SWOT分析
    Summary Lion Energy Ltd (Lion) is an oil and gas company that explores, develops and produces unconventional oil and gas resources in Indonesia. The company has conventional production sharing contracts such as Seram project and South Block A project. Its Seram project is located on the island of Se …
  • Schweizerische Rettungsflugwacht:企業の戦略的SWOT分析
    Schweizerische Rettungsflugwacht - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • China CITIC Bank Corporation Limited:企業の戦略・SWOT・財務情報
    China CITIC Bank Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China CITIC Bank Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Solvay SA (SOLB):電力:M&Aディール及び事業提携情報
    Summary Solvay SA (Solvay) is a chemical manufacturing company, which carries out production of specialty polymers, essential chemicals, silica and rare earth systems, consumer chemicals, polyamide and intermediates. In addition, the company manufactures additives, engineering plastics, diphenols an …
  • TriMas Corporation:企業のM&A・事業提携・投資動向
    TriMas Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TriMas Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Verallia Deutschland AG:企業の戦略・SWOT・財務情報
    Verallia Deutschland AG - Strategy, SWOT and Corporate Finance Report Summary Verallia Deutschland AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Serina Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Serina Therapeutics Inc (Serina Therapeutics) is a drug company that develops therapeutics for cancer, inflammation, pain, and metabolic disorders. The company’s pipeline product includes SER-214, SER-226, SER-228, SER-232, and other proprietary drugs. It uses proprietary technology, polyoxa …
  • Ridley USA Inc:企業の戦略的SWOT分析
    Ridley USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Wilbur-Ellis Company:企業の戦略・SWOT・財務情報
    Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report Summary Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Escorts Ltd:企業の戦略・SWOT・財務情報
    Escorts Ltd - Strategy, SWOT and Corporate Finance Report Summary Escorts Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ProAxsis Ltd:企業の製品パイプライン分析2018
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …
  • Weatherford International Plc (WFT):企業の財務・戦略的SWOT分析
    Weatherford International Plc (WFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • HPQ Silicon Resources Inc (HPQ):企業の財務・戦略的SWOT分析
    Summary HPQ Silicon Resources Inc (HPQ Silicon), formerly Uragold Bay Resources, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, production and development of silicon, gold and quartz properties, among others. It holds interests in The B …
  • MetLife Inc:戦略・SWOT・企業財務分析
    MetLife Inc - Strategy, SWOT and Corporate Finance Report Summary MetLife Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Broncus Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc is a medical device company that develops navigation, diagnostic and therapeutic technologies. The company’s products comprise lungpoint virtual bronchoscopic navigation system, lungpoint satellite planning system, and flexneed …
  • Insmed Inc (INSM)-医療機器分野:企業M&A・提携分析
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline includes …
  • Sompo Japan Nipponkoa Holdings, Inc.:戦略・SWOT・企業財務分析
    Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • BBX Capital Corporation:企業の戦略・SWOT・財務情報
    BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary BBX Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Quidel Corp (QDEL):医療機器:M&Aディール及び事業提携情報
    Summary Quidel Corp (Quidel) develops, manufactures and markets rapid diagnostic testing solutions for the detection and diagnosis of critical diseases and other medical conditions. Its major products include immunoassays; molecular assays; virology products including traditional cell lines, specime …
  • Achillion Pharmaceuticals Inc:企業の戦略的SWOT分析
    Achillion Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆